Phosphoramidon treatment improves the consequences of chagasic heart disease in mice

Linda A. Jelicks, Madluhika Chandra, Vitaliy Shtutin, Stefka B. Petkova, Baiyu Tang, George J. Christ, Stephen M. Factor, Murray Wittner, Huan Huang, Stephen A. Douglas, Louis M. Weiss, Pedro D'Orleans-Juste, Jamshid Shirani, Herbert B. Tanowitz

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Chagas' disease, caused by the protozoan parasite Trypanosomo cruzi, is an important cause of cardiomyopathy. Microvascular spasm and matrix dissolution, modulated by endothelin-1 (ET-1), is implicated in the pathogenesis of chagasic heart disease. To further elucidate the role of ET-1 in murine chagasic heart disease, C57BL/6 × 129sv mice were infected with T. cruzi (103 trypomastigotes of the Brazil strain). These mice are resistant to death during the acute phase but progress to chronic cardiomyopathy. Infected mice were compared with infected mice treated with phosphoramidon, a non-specific metalloprotease inhibitor that is also a potent inhibitor of endothelin-converting enzyme, at a dose of 10 mg/kg. Mice were treated with phosphoramidon for the initial 15 days post infection (PI). All mice were evaluated 200 days PI. Examination of infected, untreated mice revealed marked inflammation, vasculitis and fibrosis. The hearts of infected treated mice had significantly less pathology. Cardiac magnetic resonance imaging (MRI) revealed that right ventricular internal diameter (RVID) was significantly greater (P < 0.05) in the infected untreated group (2.9±0.22 mm) as compared with the infected treated group (1.73±0.35 mm). In another experiment phosphoramidon treatment was also tested in CDI mice, which have a high mortality during the acute phase of infection with 5 × 104 trypomastigotes of the Brazil strain. One group of CDI mice was untreated while the other group received phosphoramidon for the initial 15 days PI. The mortality rate in untreated mice was 70% by day 35 PI, while all treated infected mice lived. The parasitemia in both groups was similar. The cardiac pathology was more severe in untreated mice. MRI revealed the RVID to be significantly greater in the untreated infected group as compared with the phosphoramidon-treated infected mice (2.74±0.03 mm versus 1.64±0.4 mm P < 0.05). Transthoracic echocardiography revealed that the percentage fractional shortening was reduced in infected CDI mice but not in those infected mice treated with phosphoramidon. There was no effect of phosphoramidon in uninfected mice. Phosphoramidon (100 μg/ml) had no effect on parasites in vitro. These data are consistent with the hypothesis that ET-1 contributes to the pathogenesis of murine chagasic cardiomyopathy and suggests that interventions targeting ET-1 would improve the outcome in chagasic heart disease.

Original languageEnglish (US)
JournalClinical Science
Volume103
Issue numberSUPPL. 48
StatePublished - Aug 2002

Fingerprint

Heart Diseases
Endothelin-1
Cardiomyopathies
Infection
phosphoramidon
Brazil
Parasites
Magnetic Resonance Imaging
Pathology
Parasitemia
Chagas Disease
Mortality
Spasm
Metalloproteases
Vasculitis
Echocardiography
Fibrosis

Keywords

  • Cardiac magnetic resonance imaging
  • Chagas' disease
  • Echocardiography
  • Endothelin
  • Endothelin-converting enzyme
  • Phosphoramidon
  • Trypanosoma cruzi

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Jelicks, L. A., Chandra, M., Shtutin, V., Petkova, S. B., Tang, B., Christ, G. J., ... Tanowitz, H. B. (2002). Phosphoramidon treatment improves the consequences of chagasic heart disease in mice. Clinical Science, 103(SUPPL. 48).

Phosphoramidon treatment improves the consequences of chagasic heart disease in mice. / Jelicks, Linda A.; Chandra, Madluhika; Shtutin, Vitaliy; Petkova, Stefka B.; Tang, Baiyu; Christ, George J.; Factor, Stephen M.; Wittner, Murray; Huang, Huan; Douglas, Stephen A.; Weiss, Louis M.; D'Orleans-Juste, Pedro; Shirani, Jamshid; Tanowitz, Herbert B.

In: Clinical Science, Vol. 103, No. SUPPL. 48, 08.2002.

Research output: Contribution to journalArticle

Jelicks, LA, Chandra, M, Shtutin, V, Petkova, SB, Tang, B, Christ, GJ, Factor, SM, Wittner, M, Huang, H, Douglas, SA, Weiss, LM, D'Orleans-Juste, P, Shirani, J & Tanowitz, HB 2002, 'Phosphoramidon treatment improves the consequences of chagasic heart disease in mice', Clinical Science, vol. 103, no. SUPPL. 48.
Jelicks LA, Chandra M, Shtutin V, Petkova SB, Tang B, Christ GJ et al. Phosphoramidon treatment improves the consequences of chagasic heart disease in mice. Clinical Science. 2002 Aug;103(SUPPL. 48).
Jelicks, Linda A. ; Chandra, Madluhika ; Shtutin, Vitaliy ; Petkova, Stefka B. ; Tang, Baiyu ; Christ, George J. ; Factor, Stephen M. ; Wittner, Murray ; Huang, Huan ; Douglas, Stephen A. ; Weiss, Louis M. ; D'Orleans-Juste, Pedro ; Shirani, Jamshid ; Tanowitz, Herbert B. / Phosphoramidon treatment improves the consequences of chagasic heart disease in mice. In: Clinical Science. 2002 ; Vol. 103, No. SUPPL. 48.
@article{2b90264e20e843229474cec3eb20f357,
title = "Phosphoramidon treatment improves the consequences of chagasic heart disease in mice",
abstract = "Chagas' disease, caused by the protozoan parasite Trypanosomo cruzi, is an important cause of cardiomyopathy. Microvascular spasm and matrix dissolution, modulated by endothelin-1 (ET-1), is implicated in the pathogenesis of chagasic heart disease. To further elucidate the role of ET-1 in murine chagasic heart disease, C57BL/6 × 129sv mice were infected with T. cruzi (103 trypomastigotes of the Brazil strain). These mice are resistant to death during the acute phase but progress to chronic cardiomyopathy. Infected mice were compared with infected mice treated with phosphoramidon, a non-specific metalloprotease inhibitor that is also a potent inhibitor of endothelin-converting enzyme, at a dose of 10 mg/kg. Mice were treated with phosphoramidon for the initial 15 days post infection (PI). All mice were evaluated 200 days PI. Examination of infected, untreated mice revealed marked inflammation, vasculitis and fibrosis. The hearts of infected treated mice had significantly less pathology. Cardiac magnetic resonance imaging (MRI) revealed that right ventricular internal diameter (RVID) was significantly greater (P < 0.05) in the infected untreated group (2.9±0.22 mm) as compared with the infected treated group (1.73±0.35 mm). In another experiment phosphoramidon treatment was also tested in CDI mice, which have a high mortality during the acute phase of infection with 5 × 104 trypomastigotes of the Brazil strain. One group of CDI mice was untreated while the other group received phosphoramidon for the initial 15 days PI. The mortality rate in untreated mice was 70{\%} by day 35 PI, while all treated infected mice lived. The parasitemia in both groups was similar. The cardiac pathology was more severe in untreated mice. MRI revealed the RVID to be significantly greater in the untreated infected group as compared with the phosphoramidon-treated infected mice (2.74±0.03 mm versus 1.64±0.4 mm P < 0.05). Transthoracic echocardiography revealed that the percentage fractional shortening was reduced in infected CDI mice but not in those infected mice treated with phosphoramidon. There was no effect of phosphoramidon in uninfected mice. Phosphoramidon (100 μg/ml) had no effect on parasites in vitro. These data are consistent with the hypothesis that ET-1 contributes to the pathogenesis of murine chagasic cardiomyopathy and suggests that interventions targeting ET-1 would improve the outcome in chagasic heart disease.",
keywords = "Cardiac magnetic resonance imaging, Chagas' disease, Echocardiography, Endothelin, Endothelin-converting enzyme, Phosphoramidon, Trypanosoma cruzi",
author = "Jelicks, {Linda A.} and Madluhika Chandra and Vitaliy Shtutin and Petkova, {Stefka B.} and Baiyu Tang and Christ, {George J.} and Factor, {Stephen M.} and Murray Wittner and Huan Huang and Douglas, {Stephen A.} and Weiss, {Louis M.} and Pedro D'Orleans-Juste and Jamshid Shirani and Tanowitz, {Herbert B.}",
year = "2002",
month = "8",
language = "English (US)",
volume = "103",
journal = "Clinical Science",
issn = "0143-5221",
publisher = "Portland Press Ltd.",
number = "SUPPL. 48",

}

TY - JOUR

T1 - Phosphoramidon treatment improves the consequences of chagasic heart disease in mice

AU - Jelicks, Linda A.

AU - Chandra, Madluhika

AU - Shtutin, Vitaliy

AU - Petkova, Stefka B.

AU - Tang, Baiyu

AU - Christ, George J.

AU - Factor, Stephen M.

AU - Wittner, Murray

AU - Huang, Huan

AU - Douglas, Stephen A.

AU - Weiss, Louis M.

AU - D'Orleans-Juste, Pedro

AU - Shirani, Jamshid

AU - Tanowitz, Herbert B.

PY - 2002/8

Y1 - 2002/8

N2 - Chagas' disease, caused by the protozoan parasite Trypanosomo cruzi, is an important cause of cardiomyopathy. Microvascular spasm and matrix dissolution, modulated by endothelin-1 (ET-1), is implicated in the pathogenesis of chagasic heart disease. To further elucidate the role of ET-1 in murine chagasic heart disease, C57BL/6 × 129sv mice were infected with T. cruzi (103 trypomastigotes of the Brazil strain). These mice are resistant to death during the acute phase but progress to chronic cardiomyopathy. Infected mice were compared with infected mice treated with phosphoramidon, a non-specific metalloprotease inhibitor that is also a potent inhibitor of endothelin-converting enzyme, at a dose of 10 mg/kg. Mice were treated with phosphoramidon for the initial 15 days post infection (PI). All mice were evaluated 200 days PI. Examination of infected, untreated mice revealed marked inflammation, vasculitis and fibrosis. The hearts of infected treated mice had significantly less pathology. Cardiac magnetic resonance imaging (MRI) revealed that right ventricular internal diameter (RVID) was significantly greater (P < 0.05) in the infected untreated group (2.9±0.22 mm) as compared with the infected treated group (1.73±0.35 mm). In another experiment phosphoramidon treatment was also tested in CDI mice, which have a high mortality during the acute phase of infection with 5 × 104 trypomastigotes of the Brazil strain. One group of CDI mice was untreated while the other group received phosphoramidon for the initial 15 days PI. The mortality rate in untreated mice was 70% by day 35 PI, while all treated infected mice lived. The parasitemia in both groups was similar. The cardiac pathology was more severe in untreated mice. MRI revealed the RVID to be significantly greater in the untreated infected group as compared with the phosphoramidon-treated infected mice (2.74±0.03 mm versus 1.64±0.4 mm P < 0.05). Transthoracic echocardiography revealed that the percentage fractional shortening was reduced in infected CDI mice but not in those infected mice treated with phosphoramidon. There was no effect of phosphoramidon in uninfected mice. Phosphoramidon (100 μg/ml) had no effect on parasites in vitro. These data are consistent with the hypothesis that ET-1 contributes to the pathogenesis of murine chagasic cardiomyopathy and suggests that interventions targeting ET-1 would improve the outcome in chagasic heart disease.

AB - Chagas' disease, caused by the protozoan parasite Trypanosomo cruzi, is an important cause of cardiomyopathy. Microvascular spasm and matrix dissolution, modulated by endothelin-1 (ET-1), is implicated in the pathogenesis of chagasic heart disease. To further elucidate the role of ET-1 in murine chagasic heart disease, C57BL/6 × 129sv mice were infected with T. cruzi (103 trypomastigotes of the Brazil strain). These mice are resistant to death during the acute phase but progress to chronic cardiomyopathy. Infected mice were compared with infected mice treated with phosphoramidon, a non-specific metalloprotease inhibitor that is also a potent inhibitor of endothelin-converting enzyme, at a dose of 10 mg/kg. Mice were treated with phosphoramidon for the initial 15 days post infection (PI). All mice were evaluated 200 days PI. Examination of infected, untreated mice revealed marked inflammation, vasculitis and fibrosis. The hearts of infected treated mice had significantly less pathology. Cardiac magnetic resonance imaging (MRI) revealed that right ventricular internal diameter (RVID) was significantly greater (P < 0.05) in the infected untreated group (2.9±0.22 mm) as compared with the infected treated group (1.73±0.35 mm). In another experiment phosphoramidon treatment was also tested in CDI mice, which have a high mortality during the acute phase of infection with 5 × 104 trypomastigotes of the Brazil strain. One group of CDI mice was untreated while the other group received phosphoramidon for the initial 15 days PI. The mortality rate in untreated mice was 70% by day 35 PI, while all treated infected mice lived. The parasitemia in both groups was similar. The cardiac pathology was more severe in untreated mice. MRI revealed the RVID to be significantly greater in the untreated infected group as compared with the phosphoramidon-treated infected mice (2.74±0.03 mm versus 1.64±0.4 mm P < 0.05). Transthoracic echocardiography revealed that the percentage fractional shortening was reduced in infected CDI mice but not in those infected mice treated with phosphoramidon. There was no effect of phosphoramidon in uninfected mice. Phosphoramidon (100 μg/ml) had no effect on parasites in vitro. These data are consistent with the hypothesis that ET-1 contributes to the pathogenesis of murine chagasic cardiomyopathy and suggests that interventions targeting ET-1 would improve the outcome in chagasic heart disease.

KW - Cardiac magnetic resonance imaging

KW - Chagas' disease

KW - Echocardiography

KW - Endothelin

KW - Endothelin-converting enzyme

KW - Phosphoramidon

KW - Trypanosoma cruzi

UR - http://www.scopus.com/inward/record.url?scp=0036670316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036670316&partnerID=8YFLogxK

M3 - Article

VL - 103

JO - Clinical Science

JF - Clinical Science

SN - 0143-5221

IS - SUPPL. 48

ER -